Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 9/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3773428 | 0.91 | SMN1; SMN2 (0.54) | GFERSMN1; SMN2ALDH1A1MAPTMEN1 | |
| SCHEMBL3773986 | 0.91 | GFER (0.50) | GFERSMN1; SMN2ALDH1A1MAPTMEN1 | |
| SCHEMBL3773880 | 0.91 | GFER (0.53) | GFERSMN1; SMN2ALDH1A1MAPTMEN1 | |
| SCHEMBL3774550 | 0.89 | GFER (0.67) | GFERSMN1; SMN2ALDH1A1MAPTMEN1 | |
| SCHEMBL3761217 | 0.89 | SMN1; SMN2 (0.54) | GFERSMN1; SMN2ALDH1A1MAPTMEN1 | |
| SCHEMBL3774703 | 0.88 | GFER (0.57) | GFERSMN1; SMN2ALDH1A1MAPTMEN1 | |
| SCHEMBL3771181 | 0.88 | MAPT (0.49) | GFERSMN1; SMN2ALDH1A1MAPTMEN1 | |
| SCHEMBL3774022 | 0.88 | SMN1; SMN2 (0.53) | GFERSMN1; SMN2ALDH1A1MAPTMEN1 | |
| SCHEMBL3771074 | 0.88 | KMT2A (0.59) | GFERSMN1; SMN2ALDH1A1MAPTMEN1 | |
| SCHEMBL3779316 | 0.87 | GFER (0.56) | GFERSMN1; SMN2ALDH1A1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| WO-2007016496-A2 | DIPIPERAZINYL KETONES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | HRH4, HRH3, HRH1 | GFER 3130/4885SMN1; SMN2 4282/4885ALDH1A1 1210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.